SignatureFD’s Voyager Therapeutics VYGR Stock Holding History

SignatureFD’s Portfolio VYGR Stock Details VYGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-115	Closed	-$652	–	3465
2024 Q4	$652	Buy	+115	New	+$741	﹤0.01%	3107

Other funds holding VYGR

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SignatureFD's VYGR Position: Q1 2025 in Review

SignatureFD sold out of Voyager Therapeutics (VYGR) in Q1 2025, closing a stake of 115 shares — an estimated $652 sold.

SignatureFD first reported a position in VYGR in Q4 2024 and held it in 1 quarter. The position peaked at $652 in Q4 2024. 116 funds tracked by Wall St. Rank hold VYGR as of Q1 2025.

SignatureFD reported no remaining Voyager Therapeutics position as of Q1 2025 after selling out during the quarter.
SignatureFD sold 115 Voyager Therapeutics shares in Q1 2025, an estimated $652.
SignatureFD first reported a position in Voyager Therapeutics in Q4 2024 and held it in 1 quarter.
SignatureFD's Voyager Therapeutics position peaked at $652 in Q4 2024.
116 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q1 2025.

Based on SignatureFD's 13F filing for Q1 2025, filed 2 May 2025.